Cargando…

化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值

OBJECTIVE: To investigate the prognosis value of early and interim (18)F-FDG-PET/CT scan in patients with diffuse large B-cell lymphoma (DLBCL) to establish the suitable criteria for evaluating posttherapeutic lesions in scans. METHODS: Fifty-six newly diagnosed DLBCL patients were enrolled in the s...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364941/
https://www.ncbi.nlm.nih.gov/pubmed/26477759
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.10.004
_version_ 1783559940395237376
collection PubMed
description OBJECTIVE: To investigate the prognosis value of early and interim (18)F-FDG-PET/CT scan in patients with diffuse large B-cell lymphoma (DLBCL) to establish the suitable criteria for evaluating posttherapeutic lesions in scans. METHODS: Fifty-six newly diagnosed DLBCL patients were enrolled in the study, and underwent baseline, early and interim (18)F-FDG PET/CT scans. Five-point and % ΔSUV(max) criteria were used separately to interpret (18)F-FDG PET/CT images. Interobserver reproducibility was assessed with the kappa test (κ), and thresholds of % ΔSUV(max) were calculated via receiver operating characteristic curve (ROC). Survival curves were obtained using Kaplan-Meier curves and log-rank test. Cox regression analysis was used for multi-factor analysis. RESULTS: Median follow-up was 24 months (6 to 42 months). The kappa value of the five-point scale was above 0.600 with the reference background set in the liver (Score≥4). The optimal threshold of % ΔSUV(max) was 81% for early PET/CT and 74% for interim PET/CT. Survival analysis showed both early and interim PET/CT scans could predict the outcome of 56 patients with DLBCL, and 3-year PFS and OS of PET-negative patients were significantly higher than those of PET-positive ones (P<0.05). Five-score criteria were more accurate in evaluating 3-year PFS of DLBCL patients in the interim PET/CT scan (76.79%). % ΔSUV(max) criteria were better for interpreting 3-year OS (76.79% and 83.93%). Multi-factor analysis demonstrated that early and interim PET/CT were solid predicting factors for DLBCL patients. CONCLUSION: Early and interim PET/CT scans could predict the outcome of patients with DLBCL, treated with R-CHOP/CHOP. Three-year OS was more accurate in early and interim PET/CT using 66 %ΔSUV(max) criteria as an interpretation, while 3-year PFS was more accurate in interim PET/CT by five scores criteria.
format Online
Article
Text
id pubmed-7364941
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73649412020-07-16 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the prognosis value of early and interim (18)F-FDG-PET/CT scan in patients with diffuse large B-cell lymphoma (DLBCL) to establish the suitable criteria for evaluating posttherapeutic lesions in scans. METHODS: Fifty-six newly diagnosed DLBCL patients were enrolled in the study, and underwent baseline, early and interim (18)F-FDG PET/CT scans. Five-point and % ΔSUV(max) criteria were used separately to interpret (18)F-FDG PET/CT images. Interobserver reproducibility was assessed with the kappa test (κ), and thresholds of % ΔSUV(max) were calculated via receiver operating characteristic curve (ROC). Survival curves were obtained using Kaplan-Meier curves and log-rank test. Cox regression analysis was used for multi-factor analysis. RESULTS: Median follow-up was 24 months (6 to 42 months). The kappa value of the five-point scale was above 0.600 with the reference background set in the liver (Score≥4). The optimal threshold of % ΔSUV(max) was 81% for early PET/CT and 74% for interim PET/CT. Survival analysis showed both early and interim PET/CT scans could predict the outcome of 56 patients with DLBCL, and 3-year PFS and OS of PET-negative patients were significantly higher than those of PET-positive ones (P<0.05). Five-score criteria were more accurate in evaluating 3-year PFS of DLBCL patients in the interim PET/CT scan (76.79%). % ΔSUV(max) criteria were better for interpreting 3-year OS (76.79% and 83.93%). Multi-factor analysis demonstrated that early and interim PET/CT were solid predicting factors for DLBCL patients. CONCLUSION: Early and interim PET/CT scans could predict the outcome of patients with DLBCL, treated with R-CHOP/CHOP. Three-year OS was more accurate in early and interim PET/CT using 66 %ΔSUV(max) criteria as an interpretation, while 3-year PFS was more accurate in interim PET/CT by five scores criteria. Editorial office of Chinese Journal of Hematology 2015-10 /pmc/articles/PMC7364941/ /pubmed/26477759 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.10.004 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title_full 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title_fullStr 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title_full_unstemmed 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title_short 化疗早期及中期(18)F-FDG PET/CT显像对56例弥漫大B细胞淋巴瘤患者预后的评估价值
title_sort 化疗早期及中期(18)f-fdg pet/ct显像对56例弥漫大b细胞淋巴瘤患者预后的评估价值
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364941/
https://www.ncbi.nlm.nih.gov/pubmed/26477759
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.10.004
work_keys_str_mv AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí
AT huàliáozǎoqījízhōngqī18ffdgpetctxiǎnxiàngduì56lìmímàndàbxìbāolínbāliúhuànzhěyùhòudepínggūjiàzhí